NICE approves Keytruda, MSD’s lung cancer drug, to be used as routine treatment on the NHS

A green light has been given for lung cancer drug Keytruda by NICE for the treatment for certain patients in England. Merck, Sharp, and Dohme (MSD)’s Keytruda will be available for those with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC), where tumours have specific protein and genetic markers. Keytruda is the first treatment

Continue Reading

Pfizer to start testing respiratory syncytial virus in healthy adults

Pfizer has begun an early stage trial of an experimental vaccine against respiratory syncytial virus (RSV) in healthy adult volunteers. Pfizer is aiming to develop the vaccine for populations at highest risk of the respiratory infection, primarily infants through maternal immunisation and older adults through direct vaccination. The Phase I/II, randomised, placebo-controlled, observer-blind, dose-ranging study

Continue Reading

Pfizer treats first patient in trial for investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy

Pfizer has stated that they have begun their Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in patients with Duchenne muscular dystrophy (DMD). The first patient received an infusion of the mini-dystrophin gene, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University

Continue Reading